Zacks: ASLAN PHARMACEU/ADR (ASLN) Given Average Recommendation of “Buy” by Brokerages

ASLAN PHARMACEU/ADR (NASDAQ:ASLN) has been given an average broker rating score of 1.50 (Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and three have issued a strong buy recommendation on the company.

Analysts have set a 1 year consensus price objective of $8.88 for the company and are predicting that the company will post ($0.20) earnings per share for the current quarter, according to Zacks. Zacks has also given ASLAN PHARMACEU/ADR an industry rank of 83 out of 256 based on the ratings given to related companies.

ASLN has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating on shares of ASLAN PHARMACEU/ADR in a research report on Thursday, January 24th. Zacks Investment Research cut shares of ASLAN PHARMACEU/ADR from a “buy” rating to a “hold” rating in a research report on Tuesday, April 2nd.

A number of institutional investors and hedge funds have recently made changes to their positions in ASLN. Jane Street Group LLC acquired a new stake in shares of ASLAN PHARMACEU/ADR in the 1st quarter worth $52,000. Platinum Investment Management Ltd. increased its stake in shares of ASLAN PHARMACEU/ADR by 36.5% in the 1st quarter. Platinum Investment Management Ltd. now owns 388,395 shares of the company’s stock worth $1,666,000 after acquiring an additional 103,900 shares during the last quarter. Finally, FNY Investment Advisers LLC acquired a new stake in shares of ASLAN PHARMACEU/ADR in the 4th quarter worth $104,000. Institutional investors own 9.34% of the company’s stock.

ASLAN PHARMACEU/ADR stock traded down $0.10 during mid-day trading on Tuesday, reaching $3.60. The company had a trading volume of 5,554 shares, compared to its average volume of 3,985. ASLAN PHARMACEU/ADR has a fifty-two week low of $2.51 and a fifty-two week high of $10.44. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.64 and a quick ratio of 5.19. The firm has a market capitalization of $115.29 million and a P/E ratio of -2.57.

ASLAN PHARMACEU/ADR (NASDAQ:ASLN) last issued its earnings results on Friday, March 22nd. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.02. On average, analysts expect that ASLAN PHARMACEU/ADR will post -0.73 earnings per share for the current year.


ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.

Further Reading: Hedge Funds – Risk or Reward?

Get a free copy of the Zacks research report on ASLAN PHARMACEU/ADR (ASLN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit